{"id":"W2936108326","doi":"10.1007/s10637-019-00768-6","title":"A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Brentuximab vedotin; Medicine; CD30; Antibody-drug conjugate; Internal medicine; Adverse effect; Nausea; Mesothelioma; Oncology; Germ cell tumors; Phases of clinical research; Gastroenterology; Toxicity; Chemotherapy; Antibody; Immunology; Lymphoma; Pathology; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00106687,0.0008526093,0.001343579,0.000265359,0.0003135737,0.0005047955,0.0003990147,0.0007035338,0.002038385],"category_scores_gemma":[0.0008400176,0.000328135,0.0006537641,0.0002771608,0.0005869343,0.0005627448,0.0002007481,0.001440686,0.000395876],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005120712,"about_ca_system_score_gemma":0.001005909,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004716478,"about_ca_topic_score_gemma":0.001127214,"domain_scores_codex":[0.9996349,0.0002153208,0.0000168907,0.0000514349,0.00003673606,0.00004474383],"domain_scores_gemma":[0.9994037,0.0001556085,0.0001152342,0.00003414747,0.00004020506,0.0002511209],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6977041,0.0767085,0.02469654,0.001295737,0.0009894471,0.000926497,0.0005020427,0.003011269,0.07290784,0.0003953037,0.003565427,0.1172973],"study_design_scores_gemma":[0.4887695,0.4778624,0.02397305,0.0000357228,0.0002575683,0.0006043434,0.00007254437,0.001952653,0.003850619,0.0002532907,0.00234277,0.00002552078],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950912,0.001484188,0.0004900668,0.0001782922,0.00006023296,0.001568149,0.0005257985,0.00003655781,0.0005654873],"genre_scores_gemma":[0.9941835,0.0009123769,0.001122378,0.0003504615,0.0001499225,0.001572059,0.001042441,0.00001040719,0.0006564317],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002038385,"threshold_uncertainty_score":0.006819069,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02765653331997186,"score_gpt":0.3151312772962788,"score_spread":0.287474743976307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}